Navigation Links
Drug Shows Promise in Nervous-System Tumor Treatment
Date:7/8/2009

In small study, some patients had their hearing restored

WEDNESDAY, July 8 (HealthDay News) -- U.S. researchers report the first successful drug treatment of tumors in patients with neurofibromatosis type 2 (NF2).

In people with NF2, benign tumors develop throughout the nervous system. The most common tumor is a vestibular schwannoma, which grows on the nerve connecting the ear to the brain. This type of tumor, also called acoustic neuroma, causes hearing loss and can press on the brain stem, leading to serious neurologic symptoms and the risk of death.

Currently, these tumors are treated with surgery or radiation. This study found that treatment with the angiogenesis inhibitor bevacizumab (Avastin) shrank vestibular schwannomas, improved hearing and eased other symptoms in NF2 patients.

Bevacizumab is an anti-cancer drug designed to reduce blood flow to tumors in order to shrink them. But the drug wasn't used on acoustic neuromas because it was believed that they didn't stimulate formation of new blood vessels, as malignant tumors do.

But researchers at Massachusetts General Hospital in Boston analyzed tissue samples of NF2-related vestibular schwannomas and found evidence of excess blood vessel development. They then decided to test bevacizumab in 10 NF2 patients with vestibular schwannomas.

Tumor shrinkage occurred in nine patients, six of whom had a 20 percent or greater reduction in tumor size. The tumor shrinkage lasted between 11 and 16 months. Of the seven patients who had started to lose their hearing before treatment, four had some hearing restored. This improvement also lasted for up to 16 months.

"This kind of treatment response is unprecedented," lead author Dr. Scott Plotkin of the Pappas Center for Neuro-Oncology in the MGH Cancer Center, said in a news release. "Our study is the first to provide evidence that a drug can shrink vestibular schwannomas…and the first to show that patients' hearing can be improved."

The study will appear online in advance of publication in the July 23 issue of the New England Journal of Medicine.

More information

The U.S. National Institute of Neurological Disorders and Stroke has more about neurofibromatosis.



-- Robert Preidt



SOURCE: Massachusetts General Hospital, news release, July 8, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Study shows endoscopic surgery as effective open surgery for nasal cancer
2. Independent Laboratory Testing Shows BioNeutrals Hospital Grade Ygiene(TM) Eliminates Aspergillus Niger (Black Mold) Spores
3. CU-Boulder study shows brains immune system may cause chronic seizures
4. New Study Shows Daily Sex Can Increase Sperm Count
5. Study shows PET can measure effectiveness of novel breast cancer treatment
6. New Study Shows Many Unplanned Quit Smoking Attempts are Successful
7. Police work undermines cardiovascular health, comparison to general population shows
8. Study shows 1 in 25 deaths worldwide attributable to alcohol
9. National Survey Shows 70% of Women Have Experienced a Sexual Health Issue
10. Girls Overall Self-Worth Improves With Contact Lens Wear, Study Shows
11. New Study Shows that Prebiotics, as Used by Jackson GI Medical, Increases Lifespan by 33%
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug Shows Promise in Nervous-System Tumor Treatment 
(Date:5/2/2016)... , ... May 02, 2016 , ... Dr. Philip Shindler, ... patients with same day treatments. In the past, many necessary dental treatments could require ... along with multiple anesthetic shots and extra chair time. Not only could this be ...
(Date:5/2/2016)... Naperville, Illinois (PRWEB) , ... May 02, 2016 , ... ... our modernized mail back service. MedPro now offers its mail back service for ... this offer; we are now able to provide service to all of the clients ...
(Date:5/2/2016)... NV (PRWEB) , ... May 02, 2016 , ... ... Pharmacy Times, has announced a new Specialty Pharmacy Patient Satisfaction Award that will ... based on the quarterly results from Zitter Health Insights’ Specialty Pharmacy Patient Satisfaction ...
(Date:5/2/2016)... ... , ... The 2016 World Ultimate & Guts Championship (WUGC) Mixed roster was announced in February ... The WUGC is being held in London, England this year from June 18-25. At the ... another gold in the women’s masters division, and a silver in the women’s division, so ...
(Date:5/2/2016)... ... 02, 2016 , ... Pregnancy Awareness Month offers a great time to get ... “If you are ready to have a baby, it’s best to get started before ... is your Personal Conception & Pregnancy Organizer, written for women who plan on becoming ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)...  While Abbott,s announced purchase of St. Jude ... and stent business, healthcare research firm Kalorama Information ... into patient monitoring.  Kalorama said that patient monitoring ... with double-digit growth expected the next 5 years, ... Patient Monitoring . Abbott Laboratories agreed to ...
(Date:4/28/2016)... NEW YORK , April 28, 2016  The ... reached 275 million dollars, according to Kalorama Information and ... includes typing, immunoassays and nucleic acid testing.  The healthcare ... had made progress in developing blood collection stations and ... was made in Kalorama Information,s report, Blood ...
(Date:4/28/2016)... April 28, 2016 Oramed Pharmaceuticals Inc. ... pharmaceutical company focused on the development of oral drug delivery ... upcoming PIONEERS 2016 conference, presented by Joseph Gunnar ... New York . Nadav Kidron , ... conference. Presentation Details:   PIONEERS ...
Breaking Medicine Technology: